PLRX
PLIANT THERAPEUTICS, INC.
No net buying or selling imbalance over the last 3 months
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$0.00
0 distinct insiders
12-month sales
$0.00
0 distinct insiders
Highlighted alerts
0
0 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get PLRX insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
PLRX overview: breakout setup, X sentiment and insiders in one page →
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
- Code
- S
- Shares
- 24,002
- Price
- $1.28
- Footnotes
- 2
Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.
Reason: tax_withholding. The filing footnotes identify tax withholding. The trade is reported under a Rule 10b5-1 plan.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.